Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Diagnosis of RA for at least 1 year~* Failed at least 1 disease modifying anti-rheumatic drug (DMARD) due to toxicity or lack of efficacy. These drugs must include 1 or more of the following: methotrexate, parenteral gold, sulfasalazine, leflunomide, and tumor necrosis factor-alpha (TNFα) inhibitors (infliximab, etanercept or adalimumab)~* Active RA disease of at least moderate disease activity~* Be on a stable RA treatment regimen for at least the past 60 days (for DMARDS); if on non-steroidal anti-inflammatory drugs (NSAIDs) or steroids these must be at a stable dose for the last 30 days~Primary Exclusion Criteria:~* Received a non-FDA approved investigational agent within the last 28 days~* Currently receiving or received within the last 60 days the following: TNFα-inhibitors (infliximab, etanercept, adalimumab) or interleukin-1 receptor antagonist (anakinra)~* Currently receiving or received within the last 6 months the following: anti-CD20 antibody (rituximab) or cyclophosphamide~* Steroid injection into any joint within the last 30 days~* History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency~* History of chronic infection that has been active within last 6 months, or herpes zoster within last 90 days, or any infection requiring hospitalization or intravenous medication within last 60 days~* Human immunodeficiency virus (HIV), Hepatitis-B, Hepatitis-C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo plus SOC (Type: PLACEBO_COMPARATOR): None
- Belimumab 1 mg/kg plus SOC (Type: EXPERIMENTAL): None
- Belimumab 4 mg/kg plus SOC (Type: EXPERIMENTAL): None
- Belimumab 10 mg/kg plus SOC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).